Mexican Health Department announces agreement to promote Pharmaceutical Innovation
In order to expand the supply of innovative medicines for Mexican patients and strengthen the competitiveness of the economy, the Ministry of Health through the Federal Commission for Protection against Health Risks (COFEPRIS) announced on October 9 the next entry in force of an important Agreement on the Promotion of Pharmaceutical Innovation.
Commissioner Mikel Arriola explained that in order to support innovation, new molecules that are manufactured in Mexico – which also encourages health research – will be approved quickly and within 60 working days. At present, a new molecule registration takes up to 360 days on average.
Similarly, in order that locals have access to innovative medicines that are sold in developed countries and are not available in Mexico, COFEPRIS will recognize the registration of new molecules that have been granted by foreign agencies in the United States, Canada, Switzerland, Australia and the European Union, and approve the registrations in 60 business days.
The commissioner said that in both cases, the Mexican health agency will review and approve new drugs without neglecting the quality, safety and efficacy of drug products.